Provenge Better for African-Americans Than Men of Other Ethnicities, Analysis Shows

Provenge Better for African-Americans Than Men of Other Ethnicities, Analysis Shows
Provenge (sipuleucel-T), a treatment approved in the U.S. for metastatic castration-resistant prostate cancer, significantly increased the number of patients alive at three years, compared to a placebo, a retrospective analysis of Phase 3 clinical data shows. The treatment, which harnesses the immune system to fight cancer, was particularly effective in African-American men, researchers report. Those findings were presented in February at the 2019 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, in San Francisco, in a poster titled "
Subscribe or to access all post and page content.